Whether an exploration company or a biotech research company, if you are not generating reasonable cashflow it does not hurt to have more funds than needed for the next few years. I would be happy if they had $50m instead of <$21m. If the FDA require additional trials they will be 2 - 3x larger than the current Retts/Fragile X trials.
NEU's last Qtr costs were $2.6m and most of their research costs are in US$.
Ann: Investor Presentation, 8 January 2015, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.39 |
Change
0.130(1.06%) |
Mkt cap ! $1.529B | |||
| Open | High | Low | Value | Volume |
| $12.52 | $12.60 | $12.26 | $2.518M | 203.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 360 | $12.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.40 | 168 | 2 |
View Market Depth
| Last trade - 12.26pm 24/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |